Inactive Instrument

Press Releases CymaBay Therapeutics, Inc.

Equities

CBAY

US23257D1037

Press Releases

Unlock all the news: Be the first to know and act before the market!

Gilead Sciences - Investigational Seladelpar Demonstrates Significant Improvements in Liver Disease Progression and Reduced Itching in Primary Biliary Cholangitis	May. 20	AQ
Gilead Sciences Announces Completion of Acquisition of CymaBay	Mar. 25	AQ
CymaBay Therapeutics : Acquisition/Asset Disposal - Form 8-K	Mar. 22	PU
CymaBay Announces European Medicines Agency Accepts for Review the Marketing Authorization Application for Seladelpar for the Treatment of Primary Biliary Cholangitis	Mar. 04	AQ
CymaBay Reports Fourth Quarter and Year Ended December 31, 2023 Financial Results and Provides Corporate Update	Feb. 28	AQ
CymaBay Announces Inducement Grants Under Nasdaq Listing Rule 5635(4)	Feb. 21	AQ
CymaBay Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	Feb. 20	AQ
CYMABAY THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of CymaBay Therapeutics, Inc. - CBAY	Feb. 16	BU
Trimble, CymaBay Therapy rise; Big Lots, Monday.com fall, Monday, 2/12/2024	Feb. 12	AQ
Shareholder Alert: Ademi LLP investigates whether CymaBay Therapeutics, Inc. has obtained a Fair Price in its transaction with Gilead	Feb. 12	PR
CBAY Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of CymaBay Therapeutics, Inc. Is Fair to Shareholders	Feb. 12	BU
CymaBay Announces FDA Acceptance of NDA and Priority Review for Seladelpar for the Treatment of Primary Biliary Cholangitis	Feb. 12	PR
CymaBay Therapeutics to Participate in Upcoming Investment Conferences	Jan. 31	AQ
CymaBay Announces Inducement Grants Under Nasdaq Listing Rule 5635(4)	Jan. 17	AQ
CymaBay Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	Jan. 16	AQ
New Published Data Demonstrates Correlation Between Itch Cytokine Interleukin-31 Reduction and Pruritis Improvement in Primary Biliary Cholangitis in Phase 3 Post-Hoc Analysis of CymaBay's Seladelpar	Jan. 03	PR
CymaBay Therapeutics to Present at the 42nd Annual JP Morgan Healthcare Conference 2024	Jan. 02	AQ
CymaBay Therapeutics : Corporate Presentation	Dec. 20	PU
CymaBay Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	Dec. 18	AQ
CymaBay Submits New Drug Application to FDA for Seladelpar for the Treatment of Primary Biliary Cholangitis	Dec. 18	AQ

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Press Releases CymaBay Therapeutics, Inc.

Equities

CBAY

US23257D1037

Press Releases

Filters